Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. If you are trying to conceive and have a known or suspected thyroid condition, consult a reproductive endocrinologist or endocrinologist for evaluation and individualized treatment.
Thyroid dysfunction is one of the most common — and most correctable — hormonal barriers to conception. Affecting approximately 4–5% of women of reproductive age, thyroid disorders interfere with ovulation, implantation, and early pregnancy maintenance in ways that are measurable and, when treated, largely reversible. Yet thyroid testing is still not universally included in basic fertility workups, and subclinical thyroid disease is frequently missed until pregnancy loss prompts a more thorough investigation.
This guide covers what reproductive medicine knows about the thyroid-fertility connection, what labs you need, and how treatment changes outcomes.
How the Thyroid Affects Reproductive Function
The thyroid gland produces two hormones — thyroxine (T4) and triiodothyronine (T3) — that regulate metabolism throughout the body, including in the reproductive system. Thyroid hormones directly influence:
- Ovarian function — thyroid receptors are present on granulosa cells surrounding the developing follicle. T3 and T4 affect estrogen synthesis, follicle maturation, and the LH surge that triggers ovulation.
- Uterine receptivity — thyroid hormones influence endometrial development and the expression of implantation factors. An inadequately prepared endometrium reduces embryo implantation rates.
- Prolactin regulation — hypothyroidism raises TRH (thyrotropin-releasing hormone), which in turn elevates prolactin. Hyperprolactinemia suppresses GnRH and LH, disrupting ovulation.
- Early fetal development — the fetus relies entirely on maternal thyroid hormone for brain and nervous system development during the first trimester, before its own thyroid becomes functional.
The pituitary gland controls thyroid output via TSH (thyroid-stimulating hormone). When thyroid hormone levels are low, TSH rises to drive more production; when thyroid hormone is high, TSH is suppressed. TSH is the primary screening test for thyroid function.
Hypothyroidism and Fertility
Hypothyroidism — underactive thyroid — is the most common thyroid disorder in women of reproductive age. It is classified as:
- Overt hypothyroidism: elevated TSH with low free T4. Symptoms include fatigue, cold intolerance, weight gain, constipation, hair loss, and irregular menstrual cycles.
- Subclinical hypothyroidism (SCH): elevated TSH with normal free T4. Often asymptomatic, but clinically significant for fertility and pregnancy.
TSH thresholds for conception and pregnancy differ from standard laboratory reference ranges. Standard labs typically flag TSH as abnormal above 4.5–5.0 mIU/L. In the context of fertility and early pregnancy, the thresholds are lower:
| Stage | Recommended TSH Target |
|---|---|
| Trying to conceive | < 2.5 mIU/L |
| First trimester | < 2.5 mIU/L |
| Second trimester | < 3.0 mIU/L |
| Third trimester | < 3.5 mIU/L |
| Prior to IVF (TPO-positive) | < 1.5–2.0 mIU/L |
These targets reflect the 2017 American Thyroid Association (ATA) guidelines on thyroid disease in pregnancy and ASRM guidance on subclinical hypothyroidism in infertility management.
Treatment is straightforward: levothyroxine (synthetic T4) taken orally once daily. It is safe, inexpensive, and highly effective. TSH typically normalizes within 4–8 weeks of initiating an appropriate dose. Women already on levothyroxine who become pregnant need dose increases of approximately 25–30% immediately upon confirmed pregnancy — thyroid hormone demand rises rapidly in the first trimester.
Hyperthyroidism and Fertility
Hyperthyroidism — overactive thyroid — is less common but similarly disruptive to fertility. It is characterized by low or suppressed TSH and elevated free T4 or free T3. The most common cause in women of reproductive age is Graves' disease, an autoimmune condition in which antibodies (TSI — thyroid-stimulating immunoglobulins) mimic TSH and chronically overstimulate the thyroid gland.
Effects on fertility and pregnancy include:
- Menstrual irregularities (oligomenorrhea, amenorrhea) in moderate to severe hyperthyroidism
- Increased risk of miscarriage
- Elevated risk of preterm birth, fetal growth restriction, and placental abruption if hyperthyroidism is uncontrolled in pregnancy
- Neonatal hyperthyroidism if TSI antibodies cross the placenta (specific to Graves' disease)
Treatment options include antithyroid medications (methimazole, propylthiouracil — the latter preferred in the first trimester), radioactive iodine ablation (which permanently destroys thyroid tissue and requires waiting 6–12 months before conception), and thyroidectomy. Conception is typically recommended to be deferred until thyroid levels are well-controlled and stable on the lowest effective dose of antithyroid medication — or after definitive treatment with sufficient recovery time.
Women with Graves' disease who have previously received radioactive iodine ablation or thyroidectomy will have hypothyroidism afterward and require lifelong levothyroxine replacement — in which case the hypothyroidism guidelines above apply.
Hashimoto's Thyroiditis — The Autoimmune Factor
Hashimoto's thyroiditis is the most common cause of hypothyroidism in the developed world. It is an autoimmune condition in which the immune system attacks thyroid tissue, producing antibodies against thyroid peroxidase (anti-TPO) and thyroglobulin (anti-Tg). Over years, this immune attack gradually destroys thyroid function.
What makes Hashimoto's particularly relevant to fertility is that elevated TPO antibodies appear to negatively affect fertility and IVF outcomes even when TSH is normal. Multiple studies have documented:
- Higher miscarriage rates in TPO-positive women even with normal TSH (approximately 2–3x baseline risk in some series)
- Lower implantation rates in IVF cycles
- Higher rates of preterm birth and postpartum thyroiditis
The mechanism likely involves systemic immune dysregulation rather than thyroid hormone levels alone — the same immune environment that attacks the thyroid may impair embryo implantation and tolerance of the developing fetus.
The treatment question in TPO-positive euthyroid (normal TSH) women is actively debated. A landmark 2017 randomized controlled trial (Dhillon-Smith et al., Lancet 2019) — the TABLET trial — found that levothyroxine supplementation did not improve live birth rates in TPO-positive women with recurrent miscarriage and normal TSH. However, other studies in IVF populations suggest possible benefit. The current ATA and ASRM positions acknowledge uncertainty while recommending individualized discussion with patients, particularly those undergoing IVF.
At minimum, TPO antibody status is important diagnostic information that should guide TSH targets and monitoring intensity during treatment and pregnancy.
Thyroid and IVF — What the Research Shows
IVF imposes unique demands on thyroid function. Ovarian stimulation significantly elevates estrogen levels, and estrogen increases thyroid-binding globulin (TBG) — the protein that carries thyroid hormones in the blood. Higher TBG means more thyroid hormone is bound and less is biologically active (free), potentially unmasking subclinical hypothyroidism or worsening existing thyroid insufficiency during stimulation.
Key IVF-specific considerations:
- Women with known hypothyroidism should have TSH checked before starting an IVF cycle and the levothyroxine dose adjusted if TSH is above target
- Pre-IVF TSH target for TPO-positive women: most reproductive endocrinologists target TSH < 1.5–2.0 mIU/L before embryo transfer, given the higher implantation and miscarriage risk associated with thyroid antibodies
- TSH should be checked at the start of the stimulation cycle for known thyroid patients — the estrogen surge during stimulation can raise TSH even in well-controlled patients
- In a frozen embryo transfer (FET) cycle using estradiol supplementation, TSH monitoring is particularly important because exogenous estradiol raises TBG and can significantly shift thyroid hormone availability
A 2019 meta-analysis in Thyroid found that women with subclinical hypothyroidism who were treated with levothyroxine before IVF had significantly better clinical pregnancy and live birth rates compared to untreated controls.
Getting Tested: Which Thyroid Labs Matter
If you are trying to conceive or planning IVF, the following panel provides the most clinically meaningful thyroid picture:
| Test | Why It Matters |
|---|---|
| TSH | Primary screening test; most sensitive marker of thyroid function |
| Free T4 | Confirms whether hypothyroidism is overt (low fT4) or subclinical (normal fT4) |
| Free T3 | Less commonly required; useful if T4 is normal but symptoms persist |
| Anti-TPO antibodies | Diagnoses Hashimoto's; affects risk assessment even with normal TSH |
| Anti-Tg antibodies | Additional autoimmune marker; less specific than TPO |
| TSI (thyroid-stimulating immunoglobulin) | Specific for Graves' disease; important for pregnancy risk assessment |
Standard fertility workups do not always include anti-TPO antibodies. Ask your reproductive endocrinologist explicitly whether TPO antibody testing is part of your evaluation — particularly if you have a personal or family history of autoimmune conditions, unexplained miscarriage, or implantation failure.
Related Resources
- PCOS and Fertility — Treatment Guide
- Recurrent Miscarriage — Causes and Evaluation
- IVF Success Rates by Age — What the Data Shows
Frequently Asked Questions
What TSH level is recommended when trying to conceive?
Most reproductive endocrinologists recommend a TSH below 2.5 mIU/L when trying to conceive and below 2.5 mIU/L in the first trimester. Some guidelines suggest below 1.5 mIU/L for women undergoing IVF, particularly those with thyroid antibodies.
Does Hashimoto's thyroiditis affect IVF success?
Yes. Women with Hashimoto's thyroiditis (elevated TPO antibodies) have higher rates of implantation failure and miscarriage, even when TSH is in the normal range. Some studies show levothyroxine supplementation improves IVF outcomes in TPO-positive women with normal TSH.
Can hypothyroidism cause miscarriage?
Untreated hypothyroidism significantly increases miscarriage risk. Even subclinical hypothyroidism (elevated TSH with normal T4) is associated with a 2–3x higher miscarriage rate. Treatment with levothyroxine to normalize TSH reduces this risk substantially.
Sources: American Thyroid Association 2017 Guidelines for Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum; ASRM Practice Committee Report on Subclinical Hypothyroidism and Thyroid Autoimmunity in Infertility and Early Pregnancy (2015, reaffirmed 2022); Dhillon-Smith et al., TABLET Trial, Lancet 2019; Wang et al., meta-analysis, Thyroid 2019; Poppe et al., Human Reproduction Update 2021.
